ArticleAnnals of surgical oncology2013
Poor prognosis of advanced gastric cancer with metastatic suprapancreatic lymph nodes.
Article in Annals of surgical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Occult gastric carcinoma with microsatellite instability diagnosed 10 years after excision of metastatic lymph node: a case report.Surgical case reports · 2024Article
- Article
- Protein expression profiles and clinicopathologic characteristics associate with gastric cancer survival.Biological research · 2019Article
- Overexpression of CrkL as a novel biomarker for poor prognosis in gastric cancer.Cancer biomarkers : section A of Disease markers · 2019Article
- Prognostic significance of suprapancreatic lymph nodes and its implication on D2 dissection.Medicine · 2018Observational
- Silencing of peroxiredoxin II by promoter methylation is necessary for the survival and migration of gastric cancer cells.Experimental & molecular medicine · 2018Article
- Dysregulation of miR-126/Crk protein axis predicts poor prognosis in gastric cancer patients.Cancer biomarkers : section A of Disease markers · 2018Article
- miR-126: An indicator of poor prognosis and recurrence in histologically lymph node-negative gastric cancer.Cancer biomarkers : section A of Disease markers · 2018Article
- Down-regulated serum miR-126 is associated with aggressive progression and poor prognosis of gastric cancer.Cancer biomarkers : section A of Disease markers · 2018Article
- Serum miR-126 level combined with multi- detector computed tomography in the preoperative prediction of lymph node metastasis of gastric cancer.Cancer biomarkers : section A of Disease markers · 2018Article
- Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data.Journal of gastric cancer · 2017Article
- Low expression of fibulin-1 correlates with unfavorable prognosis in gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Risk factors associated with splenic hilar lymph node metastasis in patients with advanced gastric cancer in northwest China.International journal of clinical and experimental medicine · 2015Article
- Prognostic value of tumor size in patients with remnant gastric cancer: is the seventh UICC stage sufficient for predicting prognosis?PloS one · 2014Article
- Silencing Bmi-1 enhances the senescence and decreases the metastasis of human gastric cancer cells.World journal of gastroenterology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhether gastrectomy with D2 lymphadenectomy improves survival of patients with advanced gastric cancer (AGC) remains controversial. Few studies have described the pathological features of AGC with metastatic suprapancreatic lymph nodes (LN), which are the target of D2 lymphadenectomy. This study therefore aims to clarify the prognosis and clinical pathological features including the number and location of metastatic LN in AGC with metastatic suprapancreatic LN.
methods406 patients with AGC, who underwent gastrectomy with D2 lymphadenectomy from 1982 to 2007 at Oita University, were reviewed retrospectively with regard to presence or absence of metastatic suprapancreatic LN. The pathological factors associated with AGC with metastatic suprapancreatic LN were examined by univariate and multivariate analysis.
resultsOf 362 patients with AGC, 78 had suprapancreatic LN metastasis (21.5 %), differing significantly in terms of presence of vascular invasion and having a larger number of metastatic perigastric LN in comparison with only metastatic perigastric LN on univariate analysis. According to multivariate analysis, they were associated with presence of vascular invasion and a large number of total metastatic LN (more than two; N2≤). The overall 5-year survival rate of the AGC with perigastric LN metastasis (station 1-7) group was 37.9 % and of the AGC with suprapancreatic LN metastasis group was 12.8 %. There were significant differences in each group (P < 0.05).
conclusionsPatients with AGC with metastatic suprapancreatic LN had a large number of total metastatic LN and poor prognosis, suggesting that it may be a systemic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.